天士力(600535.SH):芪參益氣滴丸新增適應症獲臨牀試驗通知書
格隆匯1月7日丨天士力(600535.SH)公佈,近日,公司收到國家藥監局核准簽發的芪參益氣滴丸新增適應症的《臨牀試驗通知書》,並將於近期開展臨牀試驗。
芪參益氣滴丸於2003年上市銷售,為公司獨家品種。其現適應症為益氣通脈、活血止痛,用於氣虛血瘀所致胸痺,症見胸悶胸痛、氣短乏力、心悸、自汗、面色少華、舌體胖有齒痕、舌質暗或有瘀斑,脈沉弦;冠心病心絞痛見上述證候者。截至本公告日,公司對芪參益氣滴丸心衰適應症的累計研發投入為人民幣943.32萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.